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Heterocyclic molecules are of biological interest due to their
potential physical and chemical properties (Brown, 1998).
Among these, the pyrimidine compounds occupy a unique
position in pharmaceutical chemistry, as they are components
of nucleic acids. Nucleosides are the most frequently used
effective class of antiviral agents, with over twenty drugs cur-
rently approved for the treatment of viral diseases and a num-ber of candidates in the clinical trials (Mansour and Storer
1997; Bergman et al., 2004). Consequently, the intense search
for new nucleoside derivatives attracted extensive attention.
Being bioactive molecules, pyrimidines are important compo-
nents of the biological macromolecules, such as DNA and
RNA. So introducing the pyrimidines into nucleoside
derivatives may result in the discovery of a number of novel
derivatives with potential antitumor and antiviral activities.
The explosion of new approaches for their synthesis and most
importantly, their selective synthesis is an interesting subject of
organic and bioorganic chemistry.
The treatment of bacterial infections remains a challenging
therapeutic problem because of emerging infectious diseases
and the increasing number of multidrug-resistant microbial
pathogens. Despite many antibiotics and chemotherapeutics
available, the emergence of old and new antibiotic-resistant
bacterial strains in the last decades leads to a substantial need
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Pyrimidine and their derivatives are continuously attracting
attention of the medicinal chemists in view of their profound
range of biological activities, anti-HIV (Rawal et al., 2007),
analgesic agents (Chhabria et al., 2007), antiproliferative (Sche-
none et al., 2008) and antitumor (Abbas et al., 2011). The
pyrimidine nucleus has increasingly attracted the attention of
synthetic chemists. Though the antimicrobial activity of pyrim-
idine derivatives has been extensively studied and well docu-
mented in the literature (Holla et al., 2006; Chambhare et al.,
2003; Narayana et al., 2009), however, relatively few reports
were available on the anti-inﬂammatory activity of the pyrimi-
dine derivatives (Ramesh et al., 2010; Ballesteros et al., 1995;
O’Hare et al., 2011; Shishoo et al., 1999; Papadakis and Tar-
gan, 2000). In connection with such studies, the present paper
reported on the synthesis, antibacterial and antifungal activities
of (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-6-
phenylpyrimidin-4-yl) formamidine derivatives 7a–n.2. Materials and methods
2.1. General
All solvents and reagents were purchased from Sigma Al-
drich Chemicals. Melting points were determined on an elec-
trically heated VMP-III melting point apparatus. The
elemental analyses of the compounds were performed on a
Perkin Elmer 2400 Elemental Analyzer. The FT-IR spectra
were recorded using KBr discs on a FT-IR 4100 Infrared
spectrophotometer. The NMR spectra were recorded using
a Bruker DRX 400 spectrometer at 400 MHz for 1H
NMR with tetramethylsilane as the internal standard. Mass
spectral data were obtained by LC/MSD Trap XCT. Silica
gel for column chromatography was performed using Merck
7734 silica gel and Merck-made TLC plates. (E)-N0-(2-chlo-
ropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-6-phenylpyrimidin-4-
yl) formamidine derivatives 7a–n, were prepared by the
method summarized in Scheme 1.2.2. Chemistry
2.2.1. General method for the synthesis of 4-amino-2-hydroxy-6-
phenylpyrimidine-5-carbonitrile derivatives (4a–n)
The reaction of aromatic aldehyde 1a–n (10 mmol), malononit-
rile (10 mmol) and phosphorus pentoxide (3.54 mmol) is stirred
mechanically for 10 minutes in 25 ml absolute ethanol and then
thiourea (20 mmol) is added and mixed thoroughly. The result-
ing reaction mixture was heated at reﬂux and it was poured on
the crushed ice (about 200 gm) after the completion of the reac-
tion monitored by TLC. The solid was ﬁltered, washed with
petroleum ether, dried and recrystallized by using ethanol.
2.2.2. General procedure for the synthesis of N-(5-cyano-2-
hydroxy-6-phenylpyrimidin-4-yl) formamidine derivatives
(5a–n)
A solution of compound 4a–n (5.0 mmol) in formic acid
(20 mL) was reﬂuxed for 1 h. The solvent was evaporated
and the residue was crystallized from ethanol to give com-
pound 5a–n in good yield.2.2.3. General procedure for the synthesis of (E)-N0-(2-chloro-
pyrimidin-4-yl)-N-(5-cyano-2-hydroxy-6-phenylpyrimidin-4-yl)
formamidine derivatives (7a–n)
The Schiff basewas prepared by reaction of equimole of 5a–n and
2-chloropyrimidin-4-amine. Each reactant was dissolved in a
minimum amount of ethanol, then mixed together and followed
by addition of 2 ml glacial acetic acid. The solution was reﬂuxed
for 8 h then cooled to room temperature and poured into ice cold
water. The solid productwas collected throughﬁltration and then
dried using drying oven at 80 C. The product was redissolved in
ethanol for recrystallization and then dried to give a product.
2.2.3.1. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-phenylpyrimidin-4-yl)formamidine (7a). Recrystallization
from ethanol afforded 80. FT-IR (KBr, cm1) m: 3560 (O–
H), 3271 (N–H), 2220 (CN), 1697 (C‚N). 1H NMR
(DMSO-d6, 400 MHz) d: 7.15–7.57 (m, 5H, Ar–H), 7.70–7.91
(d, 2H. Pyrimidine), 8.54 (s, 1H, N‚CH), 8.93 (s, 1H, NH),
10.67 (bs, 1H, OH). MS (ESI) m/z: 352. Anal. Calcd. For
C16H10ClN7O (in%): C, 54.63; H, 2.87; N, 27.87. Found. C,
54.61; H, 2.82; N, 27.95.
2.2.3.2. (E)-N-(6-(4-chlorophenyl)-5-cyano-2-hydroxypyrimi-
din-4-yl)-N0-(2-chloropyrimidin-4-yl) formamidine (7b). Re-
crystallization from ethanol afforded 82%. FT-IR (KBr,
cm1) m: 3563 (O–H), 3276 (N–H), 2226 (CN), 1694 (C‚N).
1H NMR (DMSO-d6, 400 MHz) d: 7.31–7.51 (m, 4H, Ar–
H), 7.72–7.93 (d, 2H. Pyrimidine), 8.52 (s, 1H N‚CH), 8.92
(s, 1H NH), 10.67 (bs, 1H OH). MS (ESI) m/z: 386. Anal.
Calcd. For C16H9Cl2N7O (in%): C, 49.76; H, 2.35; N, 25.39.
Found C, 49.71; H, 2.36; N, 25.32.
2.2.3.3. (E)-N-(6-(4-bromophenyl)-5-cyano-2-hydroxypyrimi-
din-4-yl)-N0-(2-chloropyrimidin-4-yl) formamidine (7c). Recrys-
tallization from ethanol afforded 70%. FT-IR (KBr, cm1)
m: 3566 (O–H), 3269 (N–H), 2219 (CN), 1690 (C‚N). 1H
NMR (DMSO-d6, 400 MHz) d: 7.32–7.44 (m, 4H, Ar–H),
7.74–7.91 (d, 2H. Pyrimidine), 8.57 (s, 1H N‚CH), 8.94 (s,
1H NH), 10.65 (bs, 1H OH). MS (ESI) m/z: 431. Anal. Calcd.
For C16H9BrClN7O (in%): C, 44.62; H, 2.11; N, 22.77. Found
C, 44.69; H, 2.15; N, 22.71.
2.2.3.4. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-o-tolylpyrimidin-4-yl)formamidine (7d). Recrystallization from
ethanol afforded 78%. FT-IR (KBr, cm1) m: 3569 (O–H),
3271 (N–H), 2221 (CN), 1692 (C‚N). 1H NMR (DMSO-d6,
400 MHz) d: 2.50 (s, 3H, Ar–CH3), 7.33–7.48 (m, 4H, Ar–
H), 7.73–7.95 (d, 2H. Pyrimidine), 8.46 1H N‚CH), (s, 8.95
(s, 1H NH), 10.67 (bs, 1H OH). MS (ESI) m/z: 366. Anal.
Calcd. For C17H12ClN7O (in%): C, 55.82; H, 3.31; N, 26.81.
Found C, 55.87; H, 3.36; N, 26.85.
2.2.3.5. (E)-N-(6-(3-chlorophenyl)-5-cyano-2-hydroxypyrimi-
din-4-yl)-N0-(2-chloropyrimidin-4-yl) formamidine (7e).
Recrystallization from ethanol afforded 83%. FT-IR (KBr,
cm1) m: 3560 (O–H), 3279 (N–H), 2218 (CN), 1695 (C‚N).
1H NMR (DMSO-d6, 400 MHz) d: 7.35–7.51 (m, 4H, Ar–
H), 7.71–7.92 (d, 2H. Pyrimidine), 8.49 (s, 1H N‚CH), 8.91
(s, 1H NH), 10.67 (bs, 1H OH). MS (ESI) m/z: 386. Anal.
Calcd. For C16H9Cl2N7O (in%): C, 49.76; H, 2.35; N, 25.39.
Found C, 49.71; H, 2.38; N, 25.32.
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Scheme 1 Synthesis of intermediates and title compounds.
S608 C. Mallikarjunaswamy et al.2.2.3.6. (E)-N-(6-(3-bromophenyl)-5-cyano-2-hydroxypyrimi-
din-4-yl)-N0-(2-chloropyrimidin-4-yl) formamidine (7f). Recrys-
tallization from ethanol afforded 75%. FT-IR (KBr, cm1)
m: 3569(O–H), 3273 (N–H), 2223 (CN), 1699 (C‚N). 1H
NMR (DMSO-d6, 400 MHz) d: 7.32–7.46 (m, 4H, Ar–H),
7.70–7.92 (d, 2H. Pyrimidine), 8.49 (s, 1H N‚CH), 8.95 (s,
1H NH), 10.67 (bs, 1H OH). MS (ESI) m/z: 431. Anal. Calcd.
For C16H9BrClN7O (in%): C, 44.62; H, 2.11; N, 22.77. Found
C, 44.66; H, 2.15; N, 22.72.
2.2.3.7. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-m-tolylpyrimidin-4-yl)formamidine (7g). Recrystallization
from ethanol afforded 70%. FT-IR (KBr, cm1) m: 3562 (O–
H), 3279 (N–H), 2227 (CN), 1692 (C‚N). 1H NMR
(DMSO-d6, 400 MHz) d: 2.51 (s, 3H, Ar–CH3), 7.35–7.51
(m, 4H, Ar–H), 7.71–7.95 (d, 2H. Pyrimidine), 8.50 (s, 1H
N‚CH), 8.94 (s, 1H NH), 10.67 (bs, 1H OH). MS (ESI) m/
z: 366. Anal. Calcd. For C17H12ClN7O (in%): C, 55.82; H,
3.31; N, 26.81. Found C, 55.86; H, 3.37; N, 26.84.2.2.3.8. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(4-methoxyphenyl)pyrimidin-4-yl) formamidine (7h). Recrys-
tallization from ethanol afforded 76%, mp: 205–207 C. FT-
IR (KBr, cm1) m: 3560 (O–H), 3278 (N–H), 2228 (CN),
1693(C‚N). 1H NMR (DMSO-d6, 400 MHz) d: 2.20 (s, 3H,
Ar–CH3), 7.32–7.52 (m, 4H, Ar–H), 7.69–7.91 (d, 2H. Pyrim-
idine), 8.44 (s, 1H N‚CH), 8.90 (s, 1H NH), 10.67 (bs, 1H
OH). MS (ESI) m/z: 382. Anal. Calcd. For C17H12ClN7O2
(in%): C, 53.48; H, 3.17; N, 25.68. Found C, 53.41; H, 3.13;
N, 25.64.
2.2.3.9. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(2, 3, 4-trimethylphenyl) pyrimidin-4-yl) formamidine (7i).
Recrystallization from ethanol afforded 84. FT-IR (KBr,
cm1) m: 3559 (O–H), 3269 (N–H), 2217 (CN), 1689 (C‚N).
1H NMR (DMSO-d6, 400 MHz) d: 2.20–2.61 (s, 9H, Ar–
CH3), 7.35–7.46 (m, 2H, Ar–H), 7.72–7.92 (d, 2H. Pyrimidine),
8.57 (s, 1H N‚CH), 8.96 (s, 1H NH), 10.67 (bs, 1H OH). MS
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57.94; H, 4.09; N, 24.90. Found C, 57.91; H, 4.12; N, 24.97.
2.2.3.10. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(3, 4-dimethylphenyl) pyrimidin-4-yl) formamidine (7j).
Recrystallization from ethanol afforded 81%. FT-IR (KBr,
cm1) m: 3563 (O–H), 3276 (N–H), 2226 (CN), 1694 (C‚N).
1H NMR (DMSO-d6, 400 MHz) d: 2.31–2.70 (s, 6H, Ar–
CH3), 7.33–7.46 (m, 3H, Ar–H), 7.71–7.95 (d, 2H. Pyrimidine),
8.58 (s, 1H N‚CH), 8.93 (s, 1H NH), 10.67 (bs, 1H OH). MS
(ESI) m/z: 380. Anal. Calcd. For C18H14ClN7O (in%): C,
56.92; H, 3.72; N, 25.82. Found C, 56.96; H, 3.73; N,
25.87.
2.2.3.11. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(2,4-dimethylphenyl)pyrimidin-4-yl)formamidine (7k). Recrys-
tallization from ethanol afforded 79%. FT-IR (KBr, cm1)
m: 3566 (O–H), 3272 (N–H), 2228 (CN), 1691 (C‚N). 1H
NMR (DMSO-d6, 400 MHz) d: 2.11–2.52 (s, 6H, Ar–CH3),
7.34–7.49 (m, 3H, Ar–H), 7.72–7.90 (d, 2H. Pyrimidine), 8.48
(s, 1H N‚CH), 8.97 (s, 1H NH), 10.67 (bs, 1H OH).
MS (ESI) m/z: 380. Anal. Calcd. For C18H14ClN7O (in%):
C, 56.92; H, 3.72; N, 25.82. Found C, 56.97; H, 3.75; N,
25.81.
2.2.3.12. (E)-N-(6-(4-bromo-2-chlorophenyl)-5-cyano-2-
hydroxypyrimidin-4-yl)-N0-(2 chloropyrimidin-4-yl) formami-
dine (7l). Recrystallization from ethanol afforded 83%. FT-
IR (KBr, cm1) m: 3569 (O–H), 3278 (N–H), 2223 (CN),
1695 (C‚N). 1H NMR (DMSO-d6, 400 MHz) d: 7.33–7.45
(m, 3H, Ar–H), 7.72–7.94 (d, 2H. Pyrimidine), 8.53 (s, 1H
N‚CH), 8.95 (s, 1H NH), 10.67 (bs, 1H OH). MS (ESI) m/
z: 465. Anal. Calcd. For C16H8BrCl2N7O (in%): C, 41.32; H,
1.73; N, 21.08. Found C, 41.37; H, 1.74; N, 21.12.
2.2.3.13. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(4-nitrophenyl)-pyrimidin-4-yl) formamidine (7m). Recrystalli-
zation from ethanol afforded 85%. FT-IR (KBr, cm1) m: 3565
(O–H), 3271 (N–H), 2228 (CN), 1692 (C‚N). 1H NMR
(DMSO-d6, 400 MHz) d: 7.36–7.47 (m, 3H, Ar–H), 7.71–7.96
(d, 2H. Pyrimidine), 8.55 (s, 1H N‚CH), 8.91 (s, 1H NH),
10.67 (bs, 1H OH). MS (ESI) m/z: 397. Anal. Calcd. For
C16H8Cl2N8O3 (in%): C, 48.44; H, 2.29; N, 28.24. Found C,
48.46; H, 2.21; N, 28.26.
2.2.3.14. (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-
6-(2,4-imethoxyphenyl)pyrimidin-4-yl) formamidine (7n).
Recrystallization from ethanol afforded 70%. FT-IR (KBr,
cm1) m: 3272 (N–H), 3562 (O–H), 2227 (CN), 1691 (C‚N).
1H NMR (DMSO-d6, 400 MHz) d: 2.72–2.78 (s, 6H, Ar–
CH3), 7.33–7.45 (m, 3H, Ar–H), 7.72–7.92 (d, 2H. Pyrimidine),
8.46 (s, 1H N‚CH), 8.93 (s, 1H NH), 10.67 (bs, 1H OH).
MS (ESI) m/z: 412. Anal. Calcd. For C18H14ClN7O3 (in%):
C, 52.50; H, 3.43; N, 23.81. Found C, 52.55; H, 3.48; N,
23.86.
2.3. In vitro antibacterial activity
Antibacterial activity of the synthesized compounds was deter-
mined against Gram-positive bacteria (Bacillus subtilis MTCC
121, Staphylococcus aureus MTCC 7443) and Gram-negativebacteria (Xanthomonas campestris MTCC 7908 and Esche-
richia coli MTCC 7410) in DMF by the disc diffusion method
on nutrient agar medium (Bauer et al., 1966). The sterile med-
ium (Nutrient Agar Medium, 15 ml) in each petriplates was
uniformly smeared with cultures of Gram positive and Gram
negative bacteria. Sterile discs of 10 mm diameter (Hi-Media)
were placed in the petriplates, to which 50 ll (1 mg/ml i.e.,
50 lg/disc) of different synthesized compounds was added.
The treatments also included 50 ll of DMF as negative, Bacte-
riomycin and Gentamycin as positive control for comparison.
For each treatment, three replicates were maintained. The
plates were incubated at 37 ± 2 C for 24 h and the zone of
inhibition was determined.
2.4. In vitro antifungal activity
The synthesized compounds were screened for their antifungal
activity against Fusarium oxysporum MTCC 2480 in DMF by
the poisoned food technique (Satish et al., 2007). Potato Dex-
trose Agar (PDA) media was prepared and about 15 ml of
PDA was poured into each petriplate and allowed to solidify.
5 mm disc of 7 days old culture of the test fungi was placed at
the centre of the petriplates and incubated at 26 C for 7 days.
After incubation the percentage inhibition was measured and
three replicates were maintained for each treatment. Nystatin
was used as standard. All the synthesized compounds were
tested (at the dosage of 500 ll of the novel compounds/petri-
plates, where concentration was 0.1 mg/ml) by the poisoned
food technique.
3. Results and discussion
3.1. Chemistry
The subject of this work was the synthesis of heterocyclic (E)-
N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-6-phenyl-
pyrimidin-4-yl) formamidine derivatives 7a–n. The performed
reactions are shown in Scheme 1. Synthesized compounds were
characterized by elemental analyses, FT-IR, 1H NMR and
Mass spectral studies. Compounds were puriﬁed by the recrys-
tallization method using ethanol. The elemental analyses data
showed good agreement between the experimentally deter-
mined values and the theoretically calculated values within
±0.3%. Physicochemical data of the synthesized compounds
were reported in Table 1. The compounds show very good
activity towards antimicrobial and antifungal activities. So,
in regard to enhancing the biological activity of these deriva-
tives we have synthesized compounds 7a–n via formylation
and Schiff base of compounds 4a–n (Dipti et al., 2010).
The absence of NH2 absorption bands in 4a–n at 2956 cm
1
in the IR spectra conﬁrmed that the synthesized compounds
were obtained. The absorption above 3200 cm1 in com-
pounds, 7a–n conﬁrms the N–H stretching vibrations and the
appearance of medium to strong absorption bands around
1700 cm1 due to a stretching vibration of the C‚N bond for-
mation in the synthesized compounds. The proton spectral data
agree with respect to the number of proton and their chemical
shift with the proposed structure. In all the compounds 7a–n,
the disappearance of CHO and NH2 signals at d 9.80 ppm
and 4.10 ppm respectively and appearance of singlet CH proton
at d8.40–8.95 ppm are evident for synthesized compounds. The
Table 1 Physicochemical data of the synthesized compounds 7a–7n.
Compound R Structure mp (C)
7a
N
N
CN
N
H
OH
H
C
N
NN
Cl
N
N
CN
N
H
OH
H
C
N
NN
Cl
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N
N
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N
H
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H
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N
NN
Cl
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N
N
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N
H
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H
C
N
NN
Cl
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7d
N
N
CN
N
H
OH
H
C
N
NN
Cl
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7e Cl
N
N
CN
N
H
OH
H
C
N
NN
Cl
Cl 189–191
(continued on next page)
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Table 1 (continued)
Compound R Structure mp (C)
7f Br
N
N
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N
H
OH
H
C
N
NN
Cl
Br 209–211
7g
N
N
CN
N
H
OH
H
C
N
NN
Cl
182–184
7h
O
N
N
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N
H
OH
H
C
N
NN
Cl
O
205–207
7i
N
N
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N
H
OH
H
C
N
NN
Cl
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7j
N
N
CN
N
H
OH
H
C
N
NN
Cl
186–188
(continued on next page)
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Table 1 (continued)
7k
N
N
CN
N
H
OH
H
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N
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Cl
214–216
7l Br
Cl
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N
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N
H
OH
H
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N
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Cl
Br
Cl
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7m NO2
Cl
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O
O
N
N
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H
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H
C
N
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O
O
217–219
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ance of molecular ion peak in mass spectra, mass spectra of all
the newly synthesized compounds showed M+ fragmentation
peak in agreement with their molecular formula.
3.2. Antimicrobial activity
In order to search for the potent compounds from these newly
synthesized compounds 7a–n they were evaluated for in vitro
antibacterial and antifungal activity against various Gram neg-
ative, Gram positive and fungal strains. The investigation of
antibacterial screening data revealed that all tested compoundsshowed antibacterial activity against four pathogenic bacterial
strains. Among the series 7a–n, compounds 7l and 7m exhib-
ited an elevated antibacterial activity against Gram positive
(zone of inhibition 29–33 mm) and Gram negative (zone of
inhibition 32–33 mm) bacteria. Compounds 7c, 7e and 7f
showed good antibacterial activity against all the tested organ-
isms. All the remaining compounds showed moderate inhibi-
tory activity. The results were compared with standard drugs
Bacteriomycin and Gentamycin as depicted in Table 2. The
compounds 7a–n showed antimicrobial activity in the order:
7l > 7m> 7c> 7e> 7f > 7b > 7a > 7h > 7n > 7j > 7i >
7d > 7g > 7k against tested microbial strains.
Table 2 In vitro antibacterial and antifungal activities of 7a–n.
Compound Zone of inhibition in diameter (mm) % Inhibition
B. subtilis S. aureus X. campestris E. coli F. oxysporum
7a 27 25 28 29 69.5
7b 26 24 27 28 71.5
7c 31 23 29 29 78.6
7d 28 26 27 28 66.1
7e 30 27 30 30 78.4
7f 29 28 28 29 77.3
7g 29 24 26 27 64.3
7h 30 27 30 30 68.4
7i 31 26 29 29 66.7
7j 29 24 30 29 67.1
7k 28 27 26 30 61.2
7l 33 26 32 29 97.1
7m 31 29 30 32 96.9
7n 29 27 30 29 67.4
Bacteriomycin – – 34 – –
Gentamycin 35 30 – 35 –
Nystatin – – – – 100
Synthesis of novel (E)-N0-(2-chloropyrimidin-4-yl)-N-(5-cyano-2-hydroxy-6-phenylpyrimidin-4-yl) formamidine derivatives S613The in vitro antifungal activity of the synthesized compounds
7a–n was studied against F. oxysporum. The results were com-
pared with the standard drug Nystatin as in Table 2. Com-
pounds 7l and 7m showed good antifungal activity with 97.1%
and 96.9% inhibition when compared with other compounds
in the series against F. oxysporum respectively. The good inhibi-
tion by compounds 7l and 7m could be attributed to the presence
of electron withdrawing groups. Antimicrobial activity of some
pyrimidine derivatives has been reported (Keche et al., 2012).
Compounds 7c, 7e and 7f have demonstrated good antifungal
activity against F. oxysporum. Compounds 7a, 7b, 7e, 7d, 7g,
7h, 7i, 7j, 7k and 7n were found to be moderately active against
tested fungal strain. From the results it is evident thatmost of the
compounds showed moderately active and few showed good
activity. The results of the antibacterial and antifungal activities
are collected in Table 2. As in Table 2 compounds, 7l and 7m
were found to be more active than other compounds in the ser-
ies. Especially, compounds 7lwas found to be more active while
7m exhibited similar activity with respect to the standard drugs.
Compounds 7c, 7e and 7f found to have good activity. The
remaining compounds exhibited moderate antimicrobial activ-
ity. The pyrimidine derivatives containing Cl, NO2 and OCH3
of the benzene ring were found to be effective antimicrobial
agents among the series.4. Conclusion
In conclusion, the objectives of the present study were to syn-
thesize and investigate the antimicrobial activities of some new
heterocycles with the hope of discovering new structure leads
serving as potent antimicrobial agents. The obtained results
clearly revealed that compounds 7l and 7m derived from
pyrimidine exhibited better antimicrobial activity while com-
pounds 7a–k and 7n were found to be moderate antimicrobial
agents with functionalities such as Br, OCH3 and Cl groups on
the benzene ring which were found to have strong relevance to
the antimicrobial activity.Acknowledgements
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